Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

• Krystal Biotech Inc KRYS.OQ reported quarterly adjusted earnings of $1.29​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 53 cents. The mean expectation of ten analysts for the quarter was for earnings of $1.13 per share. Wall Street expected results to range from 82 cents to $1.26 per share.

• Revenue rose 36.6% to $96.04 million from a year ago; analysts expected $91.93 million.

• Krystal Biotech Inc's reported EPS for the quarter was $1.29​.

• The company reported quarterly net income of $38.33 million.

• Krystal Biotech Inc shares had risen by 14.2% this quarter and gained 0.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 24.1% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Krystal Biotech Inc is $202.00, about 22.3% above its last closing price of $156.98

This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)